Chinese regulators approve Takeda’s post-transplant CMV treatment (NYSE:TAK)

Takeda (NYSE:TAK) said Chinese regulators have approved its drug Livtencity for the treatment of adults with post-transplant CMV disease.

China’s National Medical Products Administration approved the product for the treatment of patients with post-hematopoietic stem cell transplant or solid organ transplant cytomegalovirus infection or disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.

Chinese regulators granted Breakthrough Therapy Designation for the product in 2021. The product is already approved in US, EU, Canada and Australia.